Total Revenues

Bristol-Myers Squibb·Products & Services·27 segments·Rolls up to Total Revenue

Breakdown

Segment	Q4 '23	Q1 '24	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25
Eliquis	$2.9B	$3.7B	$3.4B	$3.0B	$3.2B	$3.6B	$3.7B	$3.7B
Opdivo	$2.4B	$2.1B	$2.4B	$2.4B	$2.5B	$2.3B	$2.6B	$2.5B
Orencia	$985.0M	$798.0M	$948.0M	$936.0M	$1.0B	$770.0M	$963.0M	$964.0M
Yervoy	$566.0M	$583.0M	$630.0M	$642.0M	$675.0M	$624.0M	$728.0M	$739.0M
Pomalyst Imnovid	$890.0M	$865.0M	$959.0M	$898.0M	$823.0M	$658.0M	$708.0M	$675.0M
Reblozyl	$320.0M	$354.0M	$425.0M	$447.0M	$547.0M	$478.0M	$568.0M	$615.0M
Revlimid	$1.5B	$1.7B	$1.4B	$1.4B	$1.3B	$936.0M	$838.0M	$575.0M
Other Growth products	—	$319.0M	$341.0M	$433.0M	$512.0M	$403.0M	$470.0M	$514.0M
Breyanzi	$101.0M	$107.0M	$153.0M	$224.0M	$263.0M	$263.0M	$344.0M	$359.0M
Opdualag	$190.0M	$206.0M	$235.0M	$233.0M	$254.0M	$252.0M	$284.0M	$299.0M
Camzyos	$88.0M	$84.0M	$139.0M	$156.0M	$223.0M	$159.0M	$260.0M	$296.0M
Other Legacy products	—	$228.0M	$222.0M	$225.0M	$250.0M	$199.0M	$223.0M	$177.0M
Zeposia	$133.0M	$110.0M	$151.0M	$147.0M	$158.0M	$107.0M	$150.0M	$161.0M
Abecma	$100.0M	$82.0M	$95.0M	$124.0M	$105.0M	$103.0M	$87.0M	$137.0M
Sprycel	$526.0M	$374.0M	$424.0M	$290.0M	$198.0M	$175.0M	$120.0M	$119.0M
Sotyktu	$63.0M	$44.0M	$53.0M	$66.0M	$83.0M	$55.0M	$70.0M	$80.0M
Abraxane	$247.0M	$217.0M	$231.0M	$253.0M	$174.0M	$105.0M	$105.0M	$74.0M
Opdivo Qvantig	—	—	—	—	—	$9.0M	$30.0M	$67.0M
Krazati	—	$21.0M	$32.0M	$34.0M	$39.0M	$48.0M	$48.0M	$53.0M
Cobenfy	—	—	—	—	—	$27.0M	$35.0M	$43.0M
Net product sales	$11.2B	—	—	—	—	—	—	—
Alliance and other revenues	$309.0M	—	—	—	—	—	—	—
Alliance revenues	$147.0M	—	—	—	—	—	—	—
Other revenues	$162.0M	—	—	—	—	—	—	—
Gross product sales	$19.6B	—	—	—	—	—	—	—
Total	$11.5B	$11.9B	$12.2B	$11.9B	$12.3B	$11.2B	$12.3B	$12.2B